Sanofi, RadioMedix and Orano Med Join Forces to Develop AlphaMedix (212Pb-Dotamtate) for Rare Cancer Treatment
Shots:
- Sanofi has signed an exclusive licensing agreement with RadioMedix & Orano Med to develop AlphaMedix for unresectable/metastatic, progressive somatostatin-receptor expressing NETs
- Orano Med will handle the AlphaMedix’s manufacturing using its global industrial platform (under development) & Sanofi will commercialize it worldwide. RadioMedix & Orano Med will get ~$110.19M (€100M) upfront & ~$242.42M (€220M) sales milestones plus tiered royalties
- AlphaMedix received the US FDA’s BTD for GEP-NETs in patients naïve to peptide-receptor radionuclide therapy, based on the P-I & II trials showing 62.5% durable response rate. Its P-II study & discussions with the US FDA for regulatory approval are underway
Ref: Globenewswire | Image: Sanofi, RadioMedix and Orano Med
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
